stoxline Quote Chart Rank Option Currency Glossary
  
Vaccitech plc (VACC)
5  0.51 (11.36%)    11-06 16:00
Open: 4.6
High: 5.09
Volume: 163,052
  
Pre. Close: 4.49
Low: 4.39
Market Cap: 193(M)
Technical analysis
2024-02-02 4:25:37 PM
Short term     
Mid term     
Targets 6-month :  4.42 1-year :  5.17
Resists First :  3.78 Second :  4.42
Pivot price 3.47
Supports First :  3.17 Second :  2.79
MAs MA(5) :  3.63 MA(20) :  3.37
MA(100) :  2.95 MA(250) :  2.68
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  79 D(3) :  85
RSI RSI(14): 55.1
52-week High :  5.09 Low :  1.63
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VACC ] has closed below upper band by 43.5%. Bollinger Bands are 40% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.76 - 3.77 3.77 - 3.79
Low: 3.48 - 3.5 3.5 - 3.51
Close: 3.49 - 3.52 3.52 - 3.55
Company Description

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Headline News

Thu, 30 May 2024
Newsflash: Vaccitech plc (NASDAQ:VACC) Analysts Have Been Trimming Their Revenue Forecasts - Yahoo Movies Canada

Wed, 29 May 2024
Vaccitech plc Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Yahoo Movies UK

Thu, 21 Dec 2023
New partnership aims to advance vaccine against MERS coronavirus - GlobeNewswire

Sun, 12 Nov 2023
Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy ... - BioBuzz

Tue, 26 Sep 2023
Vaccitech plc (NASDAQ:VACC) surges 85%; individual investors who own 44% shares profited along with institutions - Yahoo Finance

Mon, 18 Sep 2023
Oxford and Liverpool scientists launch new vaccine trial for Middle East Respiratory Syndrome (MERS) - University of Oxford

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 39 (M)
Held by Insiders 2.83e+007 (%)
Held by Institutions 3.4 (%)
Shares Short 12 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -6.291e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -7 %
Return on Assets (ttm) 717.9 %
Return on Equity (ttm) -15.2 %
Qtrly Rev. Growth 1.342e+007 %
Gross Profit (p.s.) 0
Sales Per Share 0.34
EBITDA (p.s.) -1.64
Qtrly Earnings Growth -1.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -20 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 10.11
Price to Cash Flow -0.25
Stock Dividends
Dividend 0
Forward Dividend 159220
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android